Who is sponsoring NCT04303078?

NCT04303078 is sponsored by University of Washington.

What drugs are being tested in NCT04303078?

Interventions in NCT04303078: Varying levels of harness support during walking.

What condition does NCT04303078 study?

NCT04303078 studies Cerebral Palsy.

Is NCT04303078 still recruiting?

NCT04303078 is currently completed. Last updated 27 January 2026.

Are results published for NCT04303078?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-27 · How we verify

NCT04303078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quantifying Energetic Demands of Walking for People With Cerebral Palsy

Completed NA Results posted Last updated 27 January 2026

What this trial tests

NA trial testing Varying levels of harness support during walking in Cerebral Palsy in 34 participants. Completed in 17 June 2025.

Timeline

15 August 2023

Primary endpoint
17 June 2025

17 June 2025

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	34
Start date	15 August 2023
Primary completion	17 June 2025
Estimated completion	17 June 2025
Sites	1 location across United States

Drugs / interventions tested

Varying levels of harness support during walking

Conditions studied

Cerebral Palsy — all drugs for Cerebral Palsy →

Sponsor

University of Washington

Who can join

Adults 8 to 17, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Net Nondimensional Oxygen Cost Primary · Baseline walking trial with harness on (5-minutes) and support walking trials with vertical or lateral support in harness system (5-minutes)

Steady-state net nondimensional oxygen consumption while walking on a treadmill. Percent change in oxygen consumption was evaluated between baseline without support and with vertical and lateral support.

Percent Change (Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-34.13	± 21.45
Typically Developing Children (Controls)	-15.86	± 17.76

Percent Change (Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	1.07	± 7.07
Typically Developing Children (Controls)	-0.60	± 10.19

Three-dimensional Gait Kinematics (Baseline) Secondary · Initial trial without support (5-minutes)

Five features describing kinematics during gait in the harness system without vertical or lateral support collected from marker-based motion capture. Since the harness system differed between vertical and lateral support, baseline kinematics are reported separately for each system in the rows below. The features include (1) median pelvic tilt during the stance phase, (2) peak hip extension, (3) peak knee extension, (4) peak ankle plantarflexion, and (5) the foot progression angle relative to fore-aft direction.

Median Stance Pelvic Tilt (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	21.6	± 8.0
Typically Developing Children (Controls)	13.6	± 6.6

Median Stance Pelvic Tilt (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	23.4	± 9.2
Typically Developing Children (Controls)	16.2	± 7.6

Peak Stance Hip Extension (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	24.3	± 11.5
Typically Developing Children (Controls)	13.2	± 7.4

Peak Stance Hip Extension (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	27.1	± 12.0
Typically Developing Children (Controls)	16.5	± 9.5

Peak Stance Knee Extension (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	14.1	± 12.9
Typically Developing Children (Controls)	0.1	± 3.8

Peak Stance Knee Extension (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	13.3	± 10.2
Typically Developing Children (Controls)	0.5	± 6.8

Peak Stance Ankle Plantarflexion (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-1.2	± 8.7
Typically Developing Children (Controls)	-6.1	± 2.4

Peak Stance Ankle Plantarflexion (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-0.8	± 6.9
Typically Developing Children (Controls)	-5.3	± 3.4

Three-dimensional Gait Kinematics (Support) Secondary · Trial with maximum support (5-minutes)

Five features describing kinematics during gait in the harness system with vertical and lateral support. The features include (1) median pelvic tilt during the stance phase, (2) peak hip extension, (3) peak knee extension, (4) peak ankle plantarflexion, and (5) the foot progression angle relative to fore-aft direction.

Median Stance Pelvic Tilt (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	22.1	± 9.5
Typically Developing Children (Controls)	18.0	± 6.7

Median Stance Pelvic Tilt (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	23.0	± 8.3
Typically Developing Children (Controls)	16.4	± 8.3

Peak Stance Hip Extension (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	21.5	± 11.9
Typically Developing Children (Controls)	15.4	± 8.3

Peak Stance Hip Extension (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	28.0	± 10.1
Typically Developing Children (Controls)	16.1	± 9.9

Peak Stance Knee Extension (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	13.0	± 12.9
Typically Developing Children (Controls)	1.8	± 7.8

Peak Stance Knee Extension (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	15.0	± 8.8
Typically Developing Children (Controls)	0.4	± 5.3

Peak Stance Ankle Plantarflexion (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-2.0	± 9.4
Typically Developing Children (Controls)	-4.9	± 5.2

Peak Stance Ankle Plantarflexion (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-0.1	± 6.9
Typically Developing Children (Controls)	-5.1	± 2.1

Three-dimensional Gait Kinetics (Baseline) Secondary · Initial trial without support (5-minutes)

Three features describing kinetics during gait in the harness system without vertical or lateral support collected from marker-based motion capture and instrumented treadmill for ground reaction forces. Since the harness system differed between vertical and lateral support, baseline kinematics are reported separately for each system in the rows below. The features include (1) peak hip extensor moment, (2) peak knee extensor moment, and (3) peak ankle plantarflexor moment.

Peak Hip Extensor Moment (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.462	± 0.156
Typically Developing Children (Controls)	0.604	± 0.153

Peak Hip Extensor Moment (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.447	± 0.122
Typically Developing Children (Controls)	0.613	± 0.255

Peak Knee Extensor Moment (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.160	± 0.132
Typically Developing Children (Controls)	0.321	± 0.095

Peak Knee Extensor Moment (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.119	± 0.097
Typically Developing Children (Controls)	0.306	± 0.158

Peak Ankle Plantarflexor Moment (Vertical Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.026	± 0.032
Typically Developing Children (Controls)	0.068	± 0.035

Peak Ankle Plantarflexor Moment (Lateral Support - Baseline)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.033	± 0.028
Typically Developing Children (Controls)	0.074	± 0.038

Three-dimensional Gait Kinetics (Support) Secondary · Trial with maximum support (5-minutes)

Three features describing kinetics during gait in the harness system with vertical and lateral support. . Since the harness system differed between vertical and lateral support, baseline kinematics are reported separately for each system in the rows below. The features include (1) peak hip extensor moment, (2) peak knee extensor moment, and (3) peak ankle plantarflexor moment.

Peak Hip Extensor Moment (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.269	± 0.046
Typically Developing Children (Controls)	0.312	± 0.104

Peak Hip Extensor Moment (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.465	± 0.119
Typically Developing Children (Controls)	0.559	± 0.152

Peak Knee Extensor Moment (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.103	± 0.052
Typically Developing Children (Controls)	0.177	± 0.053

Peak Knee Extensor Moment (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.122	± 0.133
Typically Developing Children (Controls)	0.302	± 0.092

Peak Ankle Plantarflexor Moment (Maximum Vertical Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.012	± 0.016
Typically Developing Children (Controls)	0.035	± 0.027

Peak Ankle Plantarflexor Moment (Maximum Lateral Support)

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	0.026	± 0.031
Typically Developing Children (Controls)	0.056	± 0.031

Passive Joint Range of Motion Secondary · One-time research visit (15 minutes)

Compare passive joint range of motion (degrees) measured by lower extremity physical exam

Popliteal Angle

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	51.478	± 11.747
Typically Developing Children (Controls)	34.000	± 9.416

Maximum Knee Extension

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	-0.435	± 6.940
Typically Developing Children (Controls)	-4.700	± 4.523

Knee Extensor Lag

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	3.174	± 6.336
Typically Developing Children (Controls)	0.000	± 0.000

Maximum Ankle Dorsiflexion

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	4.043	± 6.725
Typically Developing Children (Controls)	13.200	± 4.341

Selective Motor Control Secondary · One-time research visit (15 minutes)

Selective motor control (0 patterned movement - 2 complete isolated movement)

Hip Flexion

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	1.348	± 0.487
Typically Developing Children (Controls)	2.000	± 0.000

Hip Extension

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	1.826	± 0.388
Typically Developing Children (Controls)	2.000	± 0.000

Knee Extension

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	1.870	± 0.458
Typically Developing Children (Controls)	2.000	± 0.000

Ankle Plantarflexion

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	1.565	± 0.662
Typically Developing Children (Controls)	2.000	± 0.000

Lower Extremity Strength Secondary · One-time research visit (15 minutes)

Lower extremity strength measures by the manual muscle test (0 no muscle contraction - 5 typical muscle function)

Back Extensor Strength

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	4.391	± 1.076
Typically Developing Children (Controls)	5.000	± 0.000

Hip Extensor Strength

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	3.652	± 1.071
Typically Developing Children (Controls)	5.000	± 0.000

Knee Extensor Strength

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	4.913	± 0.417
Typically Developing Children (Controls)	5.000	± 0.000

Plantarflexor Strength

Group	Value	95% CI
Children With Cerebral Palsy (Cases)	3.130	± 1.325
Typically Developing Children (Controls)	5.000	± 0.000

Sponsor's own description

The purpose of this study is to examine the underlying mechanisms that contribute to high energy costs for people with cerebral palsy (CP) as they walk. The investigators will characterize the cost landscape of children with CP, quantifying the magnitude of cost (net nondimensional oxygen consumption) associated with walking and common sub-tasks of walking, such as supporting and stabilizing the body.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

NCT07524972 — Antenatal Magnesium Sulphate in High-Risk Preterm Patients · Phase 3 · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07342348 — Using Power Mobility Training to Promote Arm & Hand Function in Children With Cerebral Palsy · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04303078 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04303078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing